R&D News | pharmaphorum

News

Halozyme abandons its €2bn pursuit of Evotec

Halozyme Therapeutics has withdrawn its offer to acquire Evotec, saying that the German company had been unwilling to engage with negotiations

News

Neurogene drops high-dose arm in Rett study after death

The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died

News

Neuralink gets okay for its first international trial

Elon Musk's brain-computer interface (BCI) company Neuralink has been given the green light to test its device in tetraplegic patients in Canada

News

Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn

Novartis buys gene therapy specialist Kate Therapeutics for $1.1 billion, adding an early-stage rival to Sarepta's muscular dystrophy therapy Elevidys

News

Novartis raises mid-term sales outlook on pipeline promise

Novartis has raised its guidance for sales growth out to 2029 on the strength of its pipeline and the potential of late-stage R&D assets

News

Pfizer elevates Chris Boshoff to top R&D role

Pfizer has named chief oncology officer Dr Chris Boshoff to the new role of chief of R&D

Halozyme abandons its €2bn pursuit of Evotec

Neurogene drops high-dose arm in Rett study after death

Neuralink gets okay for its first international trial

Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn

Novartis raises mid-term sales outlook on pipeline promise

Pfizer elevates Chris Boshoff to top R&D role

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks